Anonymous
Guest
Anonymous
Guest
A company in this kind of trouble has no business paying billions in dividends every year.
There is no hope for growth, or even equity price stability, with this kind of payout.
Case in point, REITs, which pay 90% of their income in dividends, in exchange for tax-free status. They are currently paying out up to 20% dividends, but have no chance for growth, because only 10% of the income is available after dividend payouts.
Financial tricks like "non-GAAP" accounting will only last maybe one year or more. Furthermore, the staff cutbacks will cripple drug development activity.
The only solution? Cut the dividend. You'll be glad you did. Also, a "voluntary" temporary pay cut of 25% for all M2+ staff, until the pipeline has new promising products approved.
Paid for the Committee for Responsible Corporate Stewardship
There is no hope for growth, or even equity price stability, with this kind of payout.
Case in point, REITs, which pay 90% of their income in dividends, in exchange for tax-free status. They are currently paying out up to 20% dividends, but have no chance for growth, because only 10% of the income is available after dividend payouts.
Financial tricks like "non-GAAP" accounting will only last maybe one year or more. Furthermore, the staff cutbacks will cripple drug development activity.
The only solution? Cut the dividend. You'll be glad you did. Also, a "voluntary" temporary pay cut of 25% for all M2+ staff, until the pipeline has new promising products approved.
Paid for the Committee for Responsible Corporate Stewardship